A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Sugammadex (Primary) ; Atropine; Glycopyrrolate; Glycopyrrolate/neostigmine; Neostigmine; Neostigmine/atropine
- Indications Neuromuscular blockade
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 29 Sep 2023 Status changed from recruiting to completed.
- 06 Jul 2023 Planned End Date changed from 31 Aug 2023 to 29 Feb 2024.
- 06 Jul 2023 Planned primary completion date changed from 31 Aug 2023 to 29 Feb 2024.